New insulin strength could simplify diabetes care
NCT ID NCT03903016
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares two versions of insulin lispro—one standard strength and one double-strength—to see if they work the same in the body. About 90 adults with type 1 diabetes will receive a single dose of each in random order. The goal is to check if the stronger formula is bioequivalent, meaning it could offer a convenient alternative without changing how the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
insulin lispro
What this could lead to
If successful, this could confirm that a more concentrated insulin lispro is as effective as the standard version, offering more dosing options for people with type 1 diabetes.
What could go wrong
This is an early-phase study focused on bioequivalence, not on long-term outcomes or safety. It may not translate to real-world benefits or detect rare side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 2760001
Neuss, 41460, Germany